The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.

The effects of a new antiestrogen, droloxifene (DROL, (E)-alpha-[p-[2-(dimethylamino)ethoxy]-phenyl]-alpha'-ethyl-3- stilbenol), on human breast cancer cells in vitro and in vivo were studied. Since phenol red has a binding affinity to the estrogen receptor (ER), we studied the activities of drugs in medium with or without this indicator. Estradiol-17 beta (E2) stimulated the growth of ER-positive breast cancer cells, MCF-7, ZR-75-1 and T-47D, in medium without phenol red, but not in medium containing this indicator. In medium without phenol red, DROL had no marked effects on the growth of MCF-7 and ZR-75-1, but slightly stimulated the growth of T-47D. Tamoxifen (TAM) stimulated the growth of these 3 cells. DROL dose-dependently inhibited the E2-induced stimulation of growth of these cells in medium without phenol red, but TAM inhibited the growth only at high concentrations. The growth of ER-negative breast cancer cells, MDA-MB-231, was not influenced by E2, DROL or TAM. DROL was more effective than TAM against ER-positive Br-10 breast carcinoma in nude mice, but neither drug had effects on ER-negative MX-1 breast carcinoma. These results suggest that DROL shows an antitumor effect on ER-positive breast cancers, being less estrogenic and more antiestrogenic than TAM.

[1]  K. Pollow,et al.  Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients , 1991, American journal of clinical oncology.

[2]  T. Nakamura,et al.  Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma. , 1989, Arzneimittel-Forschung.

[3]  K. Goa,et al.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. , 1989, Drugs.

[4]  J. T. Irwin,et al.  Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-1 and T-47-D. , 1988, Cancer research.

[5]  Analysis at Eight Years by 'Nolvadex',et al.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. , 1988, British Journal of Cancer.

[6]  F. May,et al.  Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. , 1987, The Journal of biological chemistry.

[7]  B. Katzenellenbogen,et al.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.

[8]  Y. Nomura,et al.  International comparisons concerning breast cancer and steroid receptors. , 1986, Anticancer research.

[9]  B. Katzenellenbogen,et al.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Gaglia,et al.  The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: a multifactorial analysis. , 1986, European journal of cancer & clinical oncology.

[11]  U. Eppenberger,et al.  In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. , 1985, European journal of cancer & clinical oncology.

[12]  S. Sato,et al.  Differential characteristics of two newly established human breast carcinoma cell lines. , 1985, Cancer research.

[13]  V. Jordan.  Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.

[14]  L. Murphy,et al.  Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. , 1984, Cancer research.

[15]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[16]  U. Eppenberger,et al.  Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. , 1983, Journal of the National Cancer Institute.

[17]  H. Rochefort,et al.  Cellular and molecular mechanism of action of antiestrogens. , 1983, Journal of steroid biochemistry.

[18]  Adam Hk,et al.  Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. , 1980 .

[19]  L. Sternson,et al.  Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. , 1980, Cancer treatment reports.

[20]  S. Hirohashi,et al.  Hormone dependency of a serially transplantable human breast cancer (Br-10) in nude mice. , 1977, Cancer research.

[21]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[22]  I. Kawamura,et al.  Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. , 1991, Japanese journal of pharmacology.

[23]  R. Paridaens,et al.  Advanced breast cancer--new approaches to treatment: workshop report. , 1988, European journal of cancer & clinical oncology.

[24]  T. Kubota,et al.  [Hormone independent murine carcinoma BX-1 spontaneously arising from nude mouse bearing Br-10, a hormone dependent human breast carcinoma strain]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

[25]  N. Davidson,et al.  Estrogen and antiestrogen resistance in human breast cancer cell lines. , 1986, Advances in experimental medicine and biology.

[26]  P. Darbre,et al.  Effect of estradiol on human breast cancer cells in culture. , 1983, Cancer research.

[27]  B. Katzenellenbogen.  Dynamics of steroid hormone receptor action. , 1980, Annual review of physiology.

[28]  J. Patterson,et al.  Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. , 1980, Cancer treatment reports.

[29]  B. Katzenellenbogen,et al.  Estrogen and antiestrogen action in reproductive tissues and tumors. , 1979, Recent progress in hormone research.